

以斑馬魚卵產製新穎抗高血壓胜

朱書宏、黃尉東

E-mail: 364830@mail.dyu.edu.tw

摘要

高血壓 (hypertension) 疾病至今為國人十大死因之一，同時亦是罹患心血管疾病之風險因子。然隨消費者預防保健意識之提升，控制血壓相關機能性食品與類藥物營養劑之需求已日益增加，其中預防高血壓之血管緊縮素轉化?抑制胜?

(angiotensin converting enzyme inhibiting peptide, ACEIP) 更受矚目。目前國立中興大學生命科學系陳全木教授與大葉大學分子生物科技學系陳小玲教授已自 kefir grain 發酵乳原料中分離出一新穎之抗高血壓胜? (anti-hypertensive peptide No. 1, AP1)，經定序解析後發現此關鍵胜?為 κ -酪蛋白 (κ -casein) 中一特定片段之胜?，其活性表現亦優於現有市售之調節血壓健康食品產品之關鍵主成分VPP 與 IPP。本論文先以前以斑馬魚 (zebrafish, Danio rerio) 為模式動物產生抗菌蛋白 (anti-microbial peptide) 平台技術之經驗，針對上述之功能性蛋白生產進行試驗。本試驗將抗高血壓胜?AP1 基因構築於斑馬 VTG 之啟動子下游，續將之選殖入pAAV-IRES-hrGFP 及 pEGFP-N1 之表現載體，並以吳郭魚卵巢細胞株 (tilapia ovary, TO-2 cells) 分析其表現，並以顯微注射導入斑馬魚受精卵內，觀察並分析其表現位置。結果顯示於細胞轉染第 48 小時後可觀察到其綠螢光之信號，續以 RT-PCR 與西方墨點反應分析，進一步證實具綠螢光蛋白之表現。SDS PAGE 分析亦顯示 AP1 蛋白之可能表現。另將上述之載體以顯微注射之方式轉置至斑馬魚胚胎中之結果顯示，於注射後 24、72、120 及 168 小時以螢光顯微觀察於卵黃囊或肝臟皆具綠螢光之表現，此親代斑馬魚並可產製具螢光表現之第二子代斑馬魚。統計分析結果顯示，96 顆魚卵中，6 顆具螢光表現並持續表現至受精後 2 個月，可達 6.2%之成功率。因此，本試驗已將 AP1 基因成功轉置於斑馬魚基因組中，後續將可藉斑馬魚為生物反應器產製抗高血壓胜? (AP1) 並進行功能性分析。

關鍵詞：高血壓、 κ -酪蛋白、抗高血壓胜?、吳郭魚卵巢細胞株、斑馬魚

目錄

封面內頁 簽名頁 中文摘要.....	iii	英文摘要.....	v	致謝.....	vi																																																																								
目錄.....	viii	圖目錄.....	xiii	表目錄.....	xv	附錄.....	xvi																																																																						
1. 前言.....	1	2. 文獻討論.....	3	2.1 高血壓 (Hypertension) 疾病.....	3	2.2 血管緊縮素轉化? (Angiotensin converting enzyme) 與血壓調控之相關性.....	3	2.2.1 血管緊縮素轉化?抑制劑 (Angiotensin converting enzyme inhibitor) 之簡介.....	4	2.2.2 抗高血壓胜? (Anti-hypertensive peptide) 之簡介.....	5	2.3 卵巢腫瘤 (Ovarian tumor, otu) 基因之簡介.....	6	2.4 斑馬魚卵黃蛋白前質基因 (Vitellogenin, vtg) 之簡介.....	7	2.5 斑馬魚雌性專一性透明帶基因 (Female-specific zebrafish zona pellucida, zpc).....	7	2.6 斑馬魚 (Zebrafish, Danio rerio) 之簡介.....	8	2.7 轉殖基因斑馬魚作為生物反應器之應用.....	9	2.8 外源蛋白之攝取及應用.....	9	2.9 研究目的.....	10																																																				
3. 材料方法.....	12	3.1 試驗材料.....	12	3.1.1 斑馬魚.....	12	3.1.1.1 斑馬魚之飼養.....	12	3.1.1.2 斑馬魚之產卵 (Breeding).....	12	3.1.2 抗高血壓胜? (Anti-hypertensive peptide No. 1, AP1).....	13	3.1.3 載體 (Vector).....	13	3.2 試驗方法.....	13	3.2.1 質體製備.....	13	3.2.2 嵌入體片段 (Insert fragment) 之製備.....	14	3.2.3 限制?酵素切割反應 (Restriction enzyme digestion).....	14	3.2.4 連接反應 (Ligation).....	14	3.2.5 少量質體之純化.....	15	3.2.6 大量質體之純化.....	15	3.2.7 勝任細胞之製備 (Preparation of competent cells).....	17	3.2.7.1 勝任細胞之轉形.....	17	3.2.8 瓊脂膠體 (agarose) 製備與電泳分析.....	17	3.2.8.1 瓊脂膠體製備.....	18	3.2.8.2 瓊脂膠體電泳分析.....	18	3.2.9 膠體萃取 (Gel extraction).....	18	3.2.10 聚合?連鎖反應 (Polymerase chainreaction, PCR).....	19	3.2.11 構築載體之定序.....	20	3.2.12 顯微注射 (Microinjection).....	20	3.2.12.1 顯微注射針之製備 (Preparation of injection needles).....	20	3.2.12.2 顯微注射 (Microinjection).....	20	3.2.13 注射卵之螢光顯微鏡觀察.....	21	3.2.14 細胞培養.....	22	3.2.14.1 細胞株之培養條件.....	22	3.2.14.2 細胞株之繼代培養.....	22	3.2.14.3 細胞轉染.....	23	3.2.15 西方墨點 (Western blot) 分析.....	24	3.2.15.1 細胞蛋白質之萃取.....	24	3.2.15.2 蛋白質定量.....	25	3.2.15.3 配製 SDS-PAGE 膠體.....	25	3.2.15.4 SDS-PAGE 分析.....	25	3.2.15.5 電轉印 (Electroblotting).....	26	3.2.15.6 西方墨點反應 (Western blot).....	26	3.2.16 細胞 RNA 之萃取.....	27	3.2.17 反轉錄聚合?連鎖反應 (Reverse transcription polymerase chain	

reaction,RT-PCR)	28	3.3 統計分析.....	29	第四章 結果.....	30	4.1 質體 pAAV-VTG-AP1 及 pEGFP-N1-AP1 之構築.....	30
4.1.1 抗高血壓勝? (AP1) 構築於 pAAV 及 pEGFP-N1 之表現載體.....	30	4.1.2 質體 pAAV-VTG-AP1 及 pEGFP-N1-AP1 之驗證.....	30	4.3 抗高血壓勝? (AP1) 及 VTG 啟動子基因於 pAAV 載體之序列分析.....	31	4.4 抗高血壓勝? 基因質體之功能活性分析.....	31
4.4.1 TO-2 細胞轉染.....	31	4.4.2 反轉錄聚合?連鎖反應 (RT-PCR) 及西方墨點反應 (Western blot) 之分析.....	31	4.4.3 Coomassie Brilliant Blue 染色法分析.....	32	4.5 斑馬魚卵顯微注射之分析與觀察.....	32
4.6 斑馬魚第一子代基因轉殖分析.....	32	第五章 討論.....	33	第六章 結論.....	37	參考文獻.....	66

參考文獻

1. Antonios TF, MacGregor GA. 1995. Angiotensin converting enzyme inhibitors in hypertension: potential problems. *J Hypertens Suppl* 13:S11-16. drugs in UK General Practice Research Database. *Bmj* 344:e2697.
2. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. 2012. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive. *BMJ* 344:e2697.
3. Brown NJ, Vaughan DE. 1998. Angiotensin-converting enzyme inhibitors. *Circulation* 97:1411-1420.
4. Chen, H. L., Hsu, P. C., Mo, M. H., Lee, S. Y., Wu, J. L., Lu, J. K., and Huang, W. T. 2009. Antimicrobial peptides (Monodoncins) production in zebrafish (*Danio rerio*) oocytes – a new bioreactor. In “ Proc. Symp. of the 24th Joint Annual Conference of Biomedical Science ”, Taipei, Taiwan. P-548.
5. Chen, H. L., Mo, M. H., He, Y. C., Tseng, Y. J., Wu, J. L., Lu, J. K., and Huang, W. T. 2008. Zebrafish (*Danio rerio*) as a bioreactor for the production of antimicrobial peptides (monodoncin) in oocytes. In “ Proc. Symp. of the 23th Joint Annual Conference of Biomedical Science ”, Taipei, Taiwan. P-384.
6. Chen, T. L., Lo, Y. C., Hu, W. T., Wu, M. C., Chen, S. T. and Chang, H. M. 2003. Microencapsulation and modification of synthetic peptides of food proteins reduces the blood pressures of spontaneously hypertensive rats. *J. Agric. Food Chem.* 51 : 1671-1675.
7. Chu J, Sadler KC. 2009. New school in liver development: lessons from zebrafish. *Hepatology* 50:1656-1663.
8. Clelland E, Peng C. 2009. Endocrine/paracrine control of zebrafish ovarian development. *Mol Cell Endocrinol* 312:42-52.
9. Devlin B, Roeder K, Wasserman L. 2001. Genomic control, a new approach to genetic-based association studies. *Theor Popul Biol* 60:155-166.
10. Epifano O, Liang LF, Familiari M, Moos MC, Jr., Dean J. 1995. Coordinate expression of the three zona pellucida genes during mouse oogenesis. *Development* 121:1947-1956.
11. FitzGerald RJ, Meisel H. 2000. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. *Br J Nutr* 84 Suppl 1:S33-37.
12. Glenn LE, Searles LL. 2001. Distinct domains mediate the early and late functions of the *Drosophila* ovarian tumor proteins. *Mech Dev* 102:181-191.
13. Gong Z, Wan H, Tay TL, Wang H, Chen M, Yan T. 2003. Development of transgenic fish for ornamental and bioreactor by strong expression of fluorescent proteins in the skeletal muscle. *Biochem Biophys Res Commun* 308:58-63.
14. Guang C, Phillips RD. 2009. Plant food-derived Angiotensin I converting enzyme inhibitory peptides. *J Agric Food Chem* 57:5113-5120.
15. Harvey AJ, Speksnijder G, Baugh LR, Morris JA, Ivarie R. 2002. Expression of exogenous protein in the egg white of transgenic chickens. *Nat Biotechnol* 20:396-399.
16. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T. 1996. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *Am J Clin Nutr* 64:767-771.
17. Hernandez-Ledesma B, Amigo L, Ramos M, Recio I. 2004. Angiotensin converting enzyme inhibitory activity in commercial fermented products. Formation of peptides under simulated gastrointestinal digestion. *J Agric Food Chem* 52:1504-1510.
18. Hwang G, Muller F, Rahman MA, Williams DW, Murdock PJ, Pasi KJ, Goldspink G, Farahmand H, Maclean N. 2004. Fish as bioreactors: transgene expression of human coagulation factor VII in fish embryos. *Mar Biotechnol (NY)* 6:485-492.
19. Lefievre L, Conner SJ, Salpekar A, Olufowobi O, Ashton P, Pavlovic B, Lenton W, Afnan M, Brewis IA, Monk M, Hughes DC, Barratt CL. 2004. Four zona - 68 - pellucida glycoproteins are expressed in the human. *Hum Reprod* 19:1580-1586.
20. Li, G. H., Le, G. W. and Shi, Y. H. 2004. Shrestha, S. Angiotensin I-converting enzyme inhibitory peptides derived from food proteins and their physical and pharmacological effects. *Nutr. Res.* 24: 469-486.
21. Li H, Aluko RE. Identification and Inhibitory Properties of Multifunctional Peptides from Pea Protein Hydrolysate. *J Agric Food Chem.*
22. Lieschke GJ, Currie PD. 2007. Animal models of human disease: zebrafish swim into view. *Nat Rev Genet* 8:353-367.
23. Makinen S, Kelloniemi J, Pihlanto A, Makinen K, Korhonen H, Hopia A, Valkonen JP. 2008. Inhibition of Angiotensin converting enzyme I caused by autolysis of potato proteins by enzymatic activities confined to different parts of the potato tuber. *J Agric Food Chem* 56:9875-9883.
24. Martin M, Wellner A, Ossowski I, Henle T. 2008. Identification and quantification of inhibitors for Angiotensin-converting enzyme in hypoallergenic infant milk formulas. *J Agric Food Chem* 56:6333-6338.
25. Martinez-Paramo S, Barbosa V, Perez-Cerezales S, Robles V, Herraes MP. 2009. Cryoprotective effects of antifreeze proteins delivered into zebrafish embryos. *Cryobiology* 58:128-133.
26. Meisel H. 1997. Biochemical properties of regulatory peptides derived from milk proteins. *Biopolymers* 43:119-128.
27. Mo S, Song P, Lv D, Chen Y, Zhou W, Gong W, Zhu Z. 2005. Zebrafish z-otu, a novel Otu and Tudor domain-containing gene, is expressed in early stages of oogenesis and embryogenesis. *Biochim Biophys Acta* 1732:1-7.
28. Nakamura Y, Yamamoto N, Sakai K, Takano T. 1995. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. *J Dairy Sci* 78:1253-1257.
29. Onichtchouk D, Aduroja K, Belting HG, Gnugge L, Driever W. 2003. Transgene driving GFP expression from the promoter of the zona pellucida gene zpc is expressed in oocytes and provides an early marker for gonad differentiation in zebrafish. *Dev Dyn* 228:393-404.
30. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM. 1982. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. *Nature* 300:611-615.
31. Patton EE, Zon LI. 2001. The art and design of genetic screens:

zebrafish. *Nat Rev Genet* 2:956-966. 32. Quiros, A., Hernandez-Ledesma, B., Ramos, M., Amigo, L. and Recio, I. 2005. Angiotensin-converting enzyme inhibitory activity of peptides derived from kefir. *J. Dairy Sci.* 88(10):3480-3487. 33. Sass GL, Comer AR, Searles LL. 1995. The ovarian tumor protein isoforms of *Drosophila melanogaster* exhibit differences in function, expression, and localization. *Dev Biol* 167:201-212. 34. Shah NP. 2000. Effects of milk-derived bioactives: an overview. *Br J Nutr* 84 Suppl 1:S3-10. 35. Smacchi, E. and Gobetti, M. 2000. Bioactive peptides in dairy products : synthesis and interaction with proteolytic enzymes. *Food Microbiol.* 17 : 129-141. 36. Steinhauer WR, Walsh RC, Kalfayan LJ. 1989. Sequence and structure of the *Drosophila melanogaster* ovarian tumor gene and generation of an antibody specific for the ovarian tumor protein. *Mol Cell Biol* 9:5726-5732. 37. Terashima M, Baba T, Ikemoto N, Katayama M, Morimoto T, Matsumura S. 2010. Novel angiotensin-converting enzyme (ACE) inhibitory peptides derived from boneless chicken leg meat. *J Agric Food Chem* 58:7432-7436. 38. Vermeirssen V, Van Camp J, Decroos K, Van Wijmelbeke L, Verstraete W. 2003. The impact of fermentation and in vitro digestion on the formation of angiotensin-I-converting enzyme inhibitory activity from pea and whey protein. *J Dairy Sci* 86:429-438. 39. Wang H, Tan JT, Emelyanov A, Korzh V, Gong Z. 2005. Hepatic and extrahepatic expression of vitellogenin genes in the zebrafish, *Danio rerio*. *Gene* 356:91-100. 40. Wang J, Shi X, Du Y, Zhou B. 2011. Effects of xenoestrogens on the expression of vitellogenin (vtg) and cytochrome P450 aromatase (cyp19a and b) genes in zebrafish (*Danio rerio*) larvae. *J Environ Sci Health A Tox Hazard Subst Environ Eng* 46:960-967. 41. Yamamoto N. 1997. Antihypertensive peptides derived from food proteins. *Biopolymers* 43:129-134. 42. Yang CH, Cheng CH, Chen GD, Liao WH, Chen YC, Huang KY, Hwang PP, Hwang SP, Huang CJ. 2011. Zona pellucida domain-containing protein beta-tectorin is crucial for zebrafish proper inner ear development. *PLoS One* 6:e23078. 43. Zeng S, Gong Z. 2002. Expressed sequence tag analysis of expression profiles of zebrafish testis and ovary. *Gene* 294:45-53. 44. Zhou, M., Du, K., Ji, P. and Feng, W. 2012. Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme. *Bio. Chem.* 168 : 60-66. 45. Ziomek CA. 1998. Commercialization of proteins produced in the mammary gland. *Theriogenology* 49:139-144.